TAK-915 (1, 3, and 10?mg/kg, p.o.) dose-dependently attenuates the non-selective muscarinic antagonist scopolamine-induced memory deficits in rats. TAK-915 (3 or 10 mg/kg, p.o.) in mice produces a dose-dependent increase in 3',5'-cyclic guanosine monophosphate (cGMP) levels, with significant cGMP increases observed at a dose of 10 mg/kg. TAK-915 (3 mg/kg; p.o.; daily; for 4 days; male F344 rats) treatment significantly reduces escape latency in aged rats in the Morris water maze task [1][2].